Related Experiment Video
Updated: Aug 20, 2025
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Development and Utility of a PAK1-Selective Degrader
Hoi-Yee Chow1,2, Sofiia Karchugina1, Brian J Groendyke3
1Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States.
Abstract:
Overexpression of PAK1, a druggable kinase, is common in several malignancies, and inhibition of PAK1 by small molecules has been shown to impede the growth and survival of such cells. Potent inhibitors of PAKs 1-3 have been described, but clinical development has been hindered by recent findings that PAK2 function is required for normal cardiovascular function in adult mice. A unique allosteric PAK1-selective inhibitor, NVS-PAK1-1, provides a potential path forward, but has modest potency. Here, we report the development of BJG-05-039, a PAK1-selective degrader consisting of NVS-PAK1-1 conjugated to lenalidomide, a recruiter of the E3 ubiquitin ligase substrate adaptor Cereblon. BJG-05-039 induced selective degradation of PAK1 and displayed enhanced anti-proliferative effects relative to its parent compound in PAK1-dependent, but not PAK2-dependent, cell lines. Our findings suggest that selective PAK1 degradation may confer more potent pharmacological effects compared with catalytic inhibition and highlight the potential advantages of PAK1-targeted degradation.
Insights
Selective degradation of PAK1 (p21-activated kinase 1) using BJG-05-039 shows enhanced anti-proliferative effects in cancer cells. This approach offers a promising alternative to kinase inhibition for targeting PAK1.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Overexpression of PAK1 (p21-activated kinase 1) is prevalent in various cancers, making it a potential therapeutic target.
- Existing PAK1 inhibitors face challenges due to the essential role of PAK2 in cardiovascular function.
- NVS-PAK1-1, a selective PAK1 inhibitor, shows modest potency.
Purpose of the Study:
- To develop a novel therapeutic strategy for PAK1-dependent cancers.
- To investigate the efficacy of selective PAK1 degradation over catalytic inhibition.
- To create a more potent and selective PAK1-targeting agent.
Main Methods:
- Development of BJG-05-039, a novel PAK1 degrader by conjugating NVS-PAK1-1 with lenalidomide.
- Assessment of BJG-05-039's ability to selectively degrade PAK1 in cancer cell lines.
- Evaluation of the anti-proliferative effects of BJG-05-039 in PAK1-dependent and PAK2-dependent cell lines.
Main Results:
- BJG-05-039 successfully induced selective degradation of PAK1.
- BJG-05-039 demonstrated enhanced anti-proliferative activity compared to its parent compound in PAK1-dependent cell lines.
- No significant effects were observed in PAK2-dependent cell lines, indicating selectivity.
Conclusions:
- Selective degradation of PAK1 is a potent therapeutic strategy for PAK1-dependent malignancies.
- PAK1 degradation offers potential advantages over traditional catalytic inhibition.
- BJG-05-039 represents a promising candidate for further development in cancer therapy.
Related Concept Videos
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
00:50Anaphase Promoting Complex